Here's what has me nervous now.
I fully expect some new regulation to come down from the market action of the past two weeks.
The fundamentals of the cannabis industry continue to improve.
This looks like consolidation after a big run rather than a major shift in market character.
Was Monday's price action much ado about nothing?
The risk is that all the gains since March could be wiped out.
My feeling is that if one is into speculation, one can trade names like BABA.
Household debt in South Korea stands at 100% of GDP as Koreans borrow like mad to buy stocks in a red-hot market where short selling is banned.
An act to improve the accounting compliance of foreign U.S.-listed companies doesn't mention China, and doesn't need to.
The plan is to take off what was a successful trade and reduce the risk, leaving an investment in place somewhat composed of 'house money'.
There are three key reasons to think next year won't be a good as this year has been for the tech giants.
The popularity of special purpose acquisition companies has gotten the attention of the SEC, and now we have questions over FMCI's merger.
While I like getting involved in volatility, I don't see any edge here, only the potential to see things go ... rolling down hill.
Lenders to the Nasdaq-listed jewelry maker reportedly have discoverd that 83 tons of gold used to borrow billions appear to be copper alloy bars.
Cannabis player came under scrutiny for number of store licenses in state.
While the president is pushing coal, this corporate giant is stepping up to cut the carbon cord.
Shares of the shoe and apparel maker are reacting to reduced revenue guidance and word of government investigations into its accounting practices.
Black-market vaping has made the entire cannabis group toxic.
Several watchers and market players are deep in the weeds, tracking short action and key companies like Canopy Growth, trying to find out whether the industry has turned over a new leaf.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Earnings misses, bad planning, and product-line execution problems are all hitting the retailer, but it's the macro woes that will also hurt its competitors.
After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.
What new management means for Mylan shareholders moving forward.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.
Volatility reigns once again at the electric carmaker, which is seeing JB Straubel depart as chief technology officer.
Big-cap names have been driving the market, but some small-caps could make noise, too.
Watch closely as the government opens a broad antitrust investigation into unidentified leading online technology platforms